1
|
John T, Kohler D, Yanagawa N, Pintilie M, Li M, Panchal D, Pham N, Der S, Shepherd FA, Tsao MS. Correlation of engraftment, mutation status, and response to chemotherapy in primary tumor xenograft models of NSCLC. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
2
|
Nakamura T, Chen JP, Panchal D, Nguyen T, King SB, Chronos N, Hou D. The role of intravascular ultrasound to guide drug-eluting stents implantation. Cardiovasc Hematol Agents Med Chem 2010; 8:22-28. [PMID: 20214600 DOI: 10.2174/187152510790796147] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Serial IVUS has demonstrated significant differences in intimal hyperplasia (IH) volume between drug-eluting stent (DES) and bare metal stents (BMS) in recent clinical trials. It has also been reported that IVUS is a useful tool in determining optimal DES implantation, especially for diabetes mellitus (DM) patients. Recent data have also suggested a critical role for, IVUS guidance in reduction of risk for DES thrombosis. IVUS has been invaluable in the elucidation of DES effects on the arterial wall, offering insight into the potential mechanisms of DES failure. Therefore, in this current manuscript, we review the potential benefits of intravascular ultrasound (IVUS) during drug eluting stent (DES) implantation.
Collapse
Affiliation(s)
- T Nakamura
- Saint Joseph's Translational Research Institute/Saint Joseph's Hospital Atlanta, 5671 Peachtree Dunwoody Road NE, Atlanta, GA 30342, USA
| | | | | | | | | | | | | |
Collapse
|
3
|
John T, Li M, Panchal D, Hui F, Meng F, Bandarchi-Chamkhaleh B, Kohler D, Zhu C, Shepherd FA, Tsao M. Correlation of primary tumor engraftment in immune deficient mice and relapse rate in patients with early-stage non-small cell lung carcinoma (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.11082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11082 Background: Compared to cell lines, primary tumor xenografts potentially are more clinically relevant cancer models as they more closely reflect the phenotype and genotype of the original cancer. However, only a minority of tumors engraft successfully in severe combined immune deficient (scid) mice and can be passaged serially. Although xenograft models are used extensively, few studies have investigated whether tumors that engraft represent a distinct clinical subset. We hypothesized that NSCLC tumors with more aggressive clinical and histological features have greater engraftment capacity than those with a less aggressive phenotype. Methods: Fresh primary tumors were harvested from NSCLC patients who underwent curative resection. Tumor fragments were implanted into the subcutaneous tissue of non-obese diabetic-scid mice within 24 hrs of excision. Patient characteristics for tumors that engrafted (XG) and did not engraft (No-XG) were compared. Only tumors from patients with >1-yr follow-up were evaluated for time to progression (TTP) and to correlate clinicopathological features with engraftment. Results: Between March 2005 and October 2008, 110 tumors were implanted. Of these, 45 (41%) engrafted and were passaged serially in vivo. The histological features of the primary were retained in 93% of XG tumors. Squamous cell carcinomas engrafted significantly more than adenocarcinomas (57% versus 26%, p=0.03). There were no significant differences in differentiation grade or clinical stage between the XG and No-XG groups. XG patients had significantly shorter TTP than the No-XG group (10.19 versus 18.64 months, p=0.003). In multivariate analysis the ability to form a xenograft was an independent predictor of relapse (HR 4.15 95% CI 1.152–14.94, p=0.03). Conclusions: Xenograft models can be established from the histological spectra of NSCLC encountered in the clinical setting and mimic closely the features of their primary tumors. The capacity of these tumors to engraft may be predictive of a more aggressive phenotype and poorer clinical outcome. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. John
- Princess Margaret Hospital, Toronto, ON, Canada
| | - M. Li
- Princess Margaret Hospital, Toronto, ON, Canada
| | - D. Panchal
- Princess Margaret Hospital, Toronto, ON, Canada
| | - F. Hui
- Princess Margaret Hospital, Toronto, ON, Canada
| | - F. Meng
- Princess Margaret Hospital, Toronto, ON, Canada
| | | | - D. Kohler
- Princess Margaret Hospital, Toronto, ON, Canada
| | - C. Zhu
- Princess Margaret Hospital, Toronto, ON, Canada
| | | | - M. Tsao
- Princess Margaret Hospital, Toronto, ON, Canada
| |
Collapse
|